VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
ATHA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
ATHAAthira Pharma, Inc.
$4.34$17M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
ATHA logo

Athira Pharma, Inc.

ATHA
NASDAQ · Biotechnology
$4.34
At close - Aug 19, 4:00 PM EDT - USD
Market Cap$17M
P/E-0.2x
52W High$8.36
Volume46.29K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Binary Clinical Risk Defines Athira Financial Outlook

Athira Pharma remains in a high-stakes, pre-revenue development phase where the entire enterprise value is tethered to the success of the LIFT-AD clinical program. The company faces significant financial pressure as it navigates a persistent net loss trajector...

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsMixed
Explore valuation models
MARKET ACTION

ATHA price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

1/12 Beats

EPS beat 1 of last 12 quarters

02

Valuation risk

-101% Peers

P/E is 101% below peer median

03

Market leadership

RS 42 · Lag

Laggard (Underperforming 58% of market)

04

Mixed Trend

Mixed

Price < 50DMA but > 200DMA

Next CatalystEstimated earnings · Nov 14

Market performance

Price History →

Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
ATHA-37.64%
S&P 500 (^GSPC)+13.20%
1-Year Return
ATHA+12.44%
S&P 500 (^GSPC)+15.98%
3-Year Return
ATHA-78.08%
S&P 500 (^GSPC)+80.58%
5-Year Return
ATHA-95.61%
S&P 500 (^GSPC)+76.03%

Growth & profitability

Annual revenue & EPS trend
Revenue
-
Net income
-$106M-8.9% YoY
Free cash flow
-$46M+53.0% YoY
Operating margin
-
ROIC (TTM)-
Avg ROIC 5Y-
ROE (TTM)-290.8%
Piotroski Score2 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate1/12 (8%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q3 2026Latest
Aug 14, 2026
-$0.80-33.3%
vs -$0.60
—
vs —
Q2 2026
May 7, 2026
-$1.73+8.9%
vs -$1.90
—
vs —
Q1 2026
Feb 25, 2026
-$18.94-3191.6%
vs -$0.58
—
vs —
Q4 2025
Nov 6, 2025
-$1.68-58.5%
vs -$1.06
—
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

5 Stories
Newsfile Corp·Sep 11, 2026
Athena Announces Amalgamation of Subsidiary to Streamline Operations

Toronto, Ontario--(Newsfile Corp. - September 11, 2026) - Athena Gold Corporation (CSE: ATHA) (OTCQB: AHNRF) ("Athena" or the "Company") is pleased to announce that it has completed a vertical amalgamation under section 273 of the Business Corporations Act (British Columbia) with its wholly-owned subsidiary, Last Bounty Gold Corp. (the "Subsidiary"), effective September 10, 2026, with the resulting amalgamated company continuing on as Athena Gold Corporation while maintaining the same articles, directors and officers as prior to the completion of the amalgamation. The amalgamation was completed to simplify Athena's corporate structure, reduce administrative and compliance costs and strengthen operational efficiency.

Newsfile Corp·Sep 8, 2026
Athena Appoints Fred Leigh to Board of Directors

Toronto, Ontario--(Newsfile Corp. - September 8, 2026) - Athena Gold Corporation (CSE: ATHA) (OTCQB: AHNRF) ("Athena" or the "Company") is pleased to announce the appointment of Mr. Fred Leigh to the Company's Board of Directors (the "Board"), effective immediately.

Accesswire·Sep 8, 2026
ATHA Energy Announces Additional Results from Rib North Discovery Expanding Continuity of Mineralization from 300 metres to 1.45 Kilometres – Results Include RIBN-DD-011 Intersecting 20 m of Composite Uranium Min Including 1.3 m of High-Grade

VANCOUVER, BC / ACCESS Newswire / September 8, 2026 / HIGHLIGHTS Preliminary results from an additional seven diamond drillholes (See July 9th , 2026 News release for results from initial eight holes) completed at the RIB North Discovery (Figure 1) - as part of the ongoing 2026 Angilak Exploration Program; Mineralization at RIB North has been discovered on two separate horizons. The bulk of drilling to date, following up on the maiden discovery hole RIBN-DD-001, is located on the eastern limb of the Mineralized RIB Corridor ("MRC"), with continuity of mineralization now traced over 1.45 km (Figures 2 & 3); Drilling is focused on widely spaced step-outs, designed to outline the continuity of uranium mineralization at RIB North - the discovery remains open in all directions; All seven drillholes (RIBN-DD-010 to RIBN-DD-016A) intersected uranium mineralization, results are highlighted by: Drillhole RIBN-DD-011: Successfully targeted uranium mineralization ~250 m along strike to the northeast from RIBN-DD-001, resulting in the intersection of 20.0 m of total composite uranium mineralization2 over fifteen zones from 494.0 m to 700.5 m, including 1.3 m of high-grade mineralization2 (Figure 4).

Newsfile Corp·Sep 1, 2026
Athena Provides Drilling Update from Excelsior Springs, Nevada

Toronto, Ontario--(Newsfile Corp. - September 1, 2026) - Athena Gold Corporation (CSE: ATHA) (OTCQB: AHNRF) ("Athena" or the "Company") is pleased to provide a further exploration update from its Excelsior Springs Project ("Excelsior" or the "Project") in Nevada. Mammoth Minerals Limited (ASX: M79) ("Mammoth") has been aggressively exploring Excelsior pursuant to its option agreement to earn an 80% interest in the Project over five years, providing Athena a free-carry to Definitive Feasibility Study thereafter (see Company press releases dated June 2, 2025, and August 22, 2025).

Filtered for Athira Pharma, Inc.More Headlines
04

Compare before deciding

Benchmark ATHA against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Athira Pharma, Inc. (ATHA)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ATHA logoATHAAthira Pharma, Inc.Current
$4.34$17.12M-0.18——-290.81%—
SAVA logoSAVACassava Sciences, Inc.
$0.94$45.26M-1.80——-95.77%—
ACIU logoACIUAC Immune S.A.
$2.73$277.84M-3.20-86.92%-246.49%-99.17%—
PRAX logoPRAXPraxis Precision Medicines, Inc.
$300.65$8.38B-22.30-100%—-34.15%—
AVXL logoAVXLAnavex Life Sciences Corp.
$2.47$228.9M-4.57——-30.07%—
NRXP logoNRXPNRx Pharmaceuticals, Inc.
$3.32$57.39M-2.48—-691.81%——

Compare ATHA vs Peers

Athira Pharma, Inc. (ATHA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs SAVA

Most directly comparable listed peer for ATHA.

Scale Benchmark

vs LLY

Larger-name benchmark to compare ATHA against a more recognizable public peer.

Peer Set

Compare Top 5

vs SAVA, ACIU, PRAX, AVXL

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

ATHA SEC Filings & Documents

Athira Pharma, Inc. (ATHA) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 14, 2026·SEC

Material company update

Jun 23, 2026·SEC

Material company update

May 7, 2026·SEC

10-K Annual Reports

4
FY 2026

Mar 31, 2026·SEC

FY 2025

Feb 27, 2025·SEC

FY 2024

Feb 22, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 14, 2026·SEC

FY 2026

May 7, 2026·SEC

FY 2025

Nov 6, 2025·SEC

Get notified when ATHA posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ATHA Frequently Asked Questions

Athira Pharma, Inc. (ATHA) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is ATHA profitable?

Athira Pharma, Inc. (ATHA) reported a net loss of $141.5M for fiscal year 2025.

Dividend & Returns
What is ATHA's return on equity?

Athira Pharma, Inc. (ATHA) has a return on equity (ROE) of -290.8%. Negative ROE indicates the company is unprofitable.

What is Athira Pharma, Inc.'s free cash flow?

Athira Pharma, Inc. (ATHA) had negative free cash flow of $61.9M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in ATHA back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →